Verrica Pharmaceuticals Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
VRCA Nasdaq 2834 www.verrica.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - Sep 10th, 2026 6:05 am
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 8th, 2026 6:00 am
Verrica completes enrolment in Phase III trial of Ycanth - Aug 28th, 2026 4:47 am
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 - Aug 27th, 2026 6:00 am
Verrica Pharmaceuticals Q2 Earnings Call Highlights - Aug 7th, 2026 1:04 pm
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Aug 6th, 2026 5:10 pm
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 2:05 pm
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - Aug 6th, 2026 2:01 pm
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - Jul 30th, 2026 6:00 am
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - Jul 21st, 2026 6:00 am
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Jun 22nd, 2026 6:05 am
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - May 28th, 2026 6:05 am
Verrica Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - May 13th, 2026 6:30 am
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - May 13th, 2026 3:16 am
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... - May 12th, 2026 11:01 pm
Verrica Pharmaceuticals Q1 Earnings Call Highlights - May 12th, 2026 9:07 pm
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2026 3:15 pm